Achieve Life Sciences (ACHV) Other financing activities (2010 - 2026)
Achieve Life Sciences' (ACHV) quarterly Other financing activities came in at $21000.0 in Q1 2026, down 98.34% on a QoQ basis from $1.3 million in Q4 2025.
Achieve Life Sciences (ACHV) Other financing activities (2010 - 2026) Analysis & Trends
Achieve Life Sciences (ACHV) has 13 years of Other financing activities data on file, last reported at $21000.0 in Q1 2026.
- Quarterly Other financing activities changed N/A year-over-year to $21000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (changed N/A YoY) and the FY2025 annual result came in at $1.4 million, up 103.08% from the prior year.
- Other financing activities fell to $21000.0 in Q1 2026, from $1.3 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $56.1 million in Q1 2024 to a low of -$55.9 million in Q3 2024.
- A 5-year average of $194916.7 and a median of $89500.0 in 2022 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2022 — Other financing activities tumbled 10100.0% — and 2024, when it jumped 72770.13%.
- Tracing ACHV's Other financing activities over 5 years: stood at -$102000.0 in 2022, then surged by 247.06% to $150000.0 in 2023, then soared by 236.0% to $504000.0 in 2024, then soared by 150.99% to $1.3 million in 2025, then tumbled by 98.34% to $21000.0 in 2026.
- The last three Other financing activities figures came in at $21000.0 (Q1 2026), $1.3 million (Q4 2025), and $120000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Achieve Life Sciences | 330.88 Mn | 330.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 139,000.00 |
| Jun 30, 2026 | 139,000.00 |
| Mar 31, 2026 | 21,000.00 |
| Mar 31, 2026 | 21,000.00 |
| Dec 31, 2025 | 1.27 Mn |
| Dec 31, 2025 | 1.27 Mn |
| Sep 30, 2025 | 120,000.00 |
| Sep 30, 2025 | 120,000.00 |
| Dec 31, 2024 | 504,000.00 |
| Dec 31, 2024 | 504,000.00 |
| Sep 30, 2024 | -55.89 Mn |
| Sep 30, 2024 | -55.89 Mn |
| Jun 30, 2024 | -39,000.00 |
| Jun 30, 2024 | -39,000.00 |
| Mar 31, 2024 | 56.11 Mn |
| Mar 31, 2024 | 56.11 Mn |
| Jun 30, 2023 | 150,000.00 |
| Jun 30, 2023 | 150,000.00 |
| Mar 31, 2023 | 77,000.00 |
| Mar 31, 2023 | 77,000.00 |